Kumagai Naoki, LaMattina John C, Kamano Chisako, Vagefi Parsia A, Barth Rolf N, O'Neil John J, Yamamoto Shin, Moran Shannon G, Utsugi Ryu, Sachs David H, Yamada Kazuhiko
Transplantation Biology Research Center, Massachusetts General Hospital, Boston, Massachusetts 02129, USA.
Diabetes. 2002 Nov;51(11):3220-8. doi: 10.2337/diabetes.51.11.3220.
We have previously reported the preparation of vascularized islet-kidneys (IKs) by transplantation of islets under the autologous kidney capsule. Here, we compare the efficacy of transplanting vascularized versus nonvascularized islets into diabetic allogeneic swine recipients. In the vascularized islet transplantation (5,000 islet equivalents [IE]/kg), recipients received minor-mismatched (n = 4) or fully-mismatched (n = 2) IKs after pancreatectomy, with a 12-day course of cyclosporine A (CyA) or FK506, respectively. For the nonvascularized islet transplantation (7,000 IE/kg), three recipients received minor-mismatched islets alone and two recipients received minor-mismatched donor islets placed in a donor kidney on the day of transplantation. All recipients of nonvascularized islets were treated with a 12-day course of CyA. With vascularized islet transplantation, pancreatectomized recipients were markedly hyperglycemic pretransplant (fasting blood glucose >300 mg/dl). After composite IK transplantation, all recipients developed and maintained normoglycemia (<120 mg/dl) and stable renal function indefinitely (>3 months), and insulin therapy was not required. Major histocompatibility complex-mismatched recipients demonstrated in vitro donor-specific unresponsiveness. In contrast, recipients of nonvascularized islets remained hyperglycemic. In conclusion, IK allografts cured surgically induced diabetes across allogeneic barriers, whereas nonvascularized islet transplants did not. These data indicate that prevascularization of islet allografts is crucial for their subsequent engraftment and that composite IKs may provide a strategy for successful islet transplantation.
我们之前曾报道过通过将胰岛移植到自体肾被膜下制备血管化胰岛-肾脏(IKs)。在此,我们比较了将血管化胰岛与非血管化胰岛移植到糖尿病同种异体猪受体中的效果。在血管化胰岛移植组(5000个胰岛当量[IE]/kg)中,受体在胰腺切除术后分别接受了轻微错配(n = 4)或完全错配(n = 2)的IKs,并分别接受了为期12天的环孢素A(CyA)或FK506治疗。对于非血管化胰岛移植组(7000 IE/kg),3名受体仅接受了轻微错配的胰岛,2名受体在移植当天接受了置于供体肾脏内的轻微错配供体胰岛。所有非血管化胰岛移植的受体均接受了为期12天的CyA治疗。在血管化胰岛移植中,胰腺切除术后的受体移植前明显高血糖(空腹血糖>300 mg/dl)。复合IK移植后,所有受体均出现并维持了正常血糖水平(<120 mg/dl),且肾功能稳定(>3个月),无需胰岛素治疗。主要组织相容性复合体错配的受体表现出体外供体特异性无反应性。相比之下,非血管化胰岛移植的受体仍处于高血糖状态。总之,IK同种异体移植跨越同种异体障碍治愈了手术诱导的糖尿病,而非血管化胰岛移植则未成功。这些数据表明,胰岛同种异体移植的预先血管化对其随后的植入至关重要,复合IKs可能为成功的胰岛移植提供一种策略。